Research programme: hydroxysteroid dehydrogenase inhibitors - Pfizer
Alternative Names: Research programme: 11β-HSD1 inhibitors - PfizerLatest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Wyeth
- Developer Pfizer
- Class Piperazines; Small molecules; Sulfonamides
- Mechanism of Action 11-beta-hydroxysteroid dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
- 15 Oct 2009 Wyeth has been acquired by Pfizer